[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Genuine Research Center, Egypt\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":36,"locationsCount":4},"100506607","phase-3-clinical-trial-to-investigate-the-efficacy-and-safety-of-ondansetron-danset---adwia-versus-placebo-plus-the-standard-of-care-in-the-treatment-of-nausea-and-vomiting-in-adult-patients-with-acute-gastroenteritis-100506607",false,"NCT05876585","Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis","A Randomized, Double-Blinded, Placebo-Controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis","Inclusion Criteria:\n\n1. Male or female patients aged between 18 and 65 years.\n2. Patients diagnosed with acute gastroenteritis visiting the emergency room.\n3. Patients considered by the attending physician to need an anti-emetic medication.\n4. Patients able and willing to provide written informed consent.\n5. Patients able and willing to complete the study procedures including compliance with the requirements and restrictions listed in the consent form.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Patients who received an anti-emetic medication during the past 24 hours.\n3. History of hypersensitivity to any components of ondansetron or metoclopramide injection.\n4. History of hypersensitivity to other selective 5HT3 receptor antagonists.\n5. Patients with moderate or severe impairment of hepatic function.\n6. Patients with moderate or severe renal impairment.\n7. Patients with congenital long QT syndrome.\n8. Patients who have or may develop prolongation of Qtc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmia, or patients taking other medicinal products that lead to QT prolongation or electrolyte imbalance.\n9. Patients with hypokalemia or hypomagnesemia.\n10. Patients with signs of subacute intestinal obstruction.\n11. Patients currently using apomorphine hydrochloride.\n12. Patients currently using levodopa or dopamine agonists.\n13. Patients with gastrointestinal hemorrhage, mechanical obstruction, or gastrointestinal perforation.\n14. Patients with a known history of neuroleptic- or metoclopramide-induced tardive dyskinesia.\n15. Patients with epilepsy.\n16. Patients with Parkinson's disease.\n17. Patients with confirmed or suspected pheochromocytoma.\n18. Patients with a known history of methemoglobinemia with metoclopramide or NADH-cytochrome b5 reductase deficiency.\n19. Patients with a history of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol.\n20. Patients with any chronic illness or prior treatment which in the opinion of the investigator should preclude participation in the trial.\n21. Receipt of an investigational drug within 6 months prior to screening, or active enrolment in another investigational medication or device trial.\n22. Inability to understand and cooperate with the investigators or to give valid consent.","ALL","18 Years","65 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A Randomized, Open-label, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis.",[27],"Gastroenteritis","NOT_YET_RECRUITING","2024-09-24",{"date":31,"type":32},"2024-09-26","ACTUAL",{"date":34,"type":21},"2025-06-01",{"date":34,"type":21},{"name":37,"class":38},"Genuine Research Center, Egypt","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100506874","phase-4-study-of-bisoprolol-nerkardou---nerhadou-international-5-and-10-mg-oral-dissolvable-film-odf-treatment-in-egyptian-patients-with-essential-hypertension-100506874","NCT05880056","Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension","A Prospective, Multicenter, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension","BETTER","Inclusion Criteria:\n\n1. The participant is willing and able to give informed consent for participation in the trial.\n2. Male or Female, aged ≥ 21 and \\\u003C 65 years.\n3. The subject with Body mass index (BMI) greater than or equal to 18.5 and below 30 kg\u002Fm2\n4. Newly diagnosed hypertensive patients with grade 1 and 2 are defined according to the recent ESC\u002FESH guidelines as follows:\n\n   * Grade 1 hypertension: SBP 140 to 159mmHg and\u002For DBP 90 to 99mmHg\n   * Grade 2 hypertension: SBP 160 to 179mmHg and\u002For DBP 100 to 109mmHg at screening.\n5. Non-responders to the 1ST line of therapy for hypertension other than beta blocker and can be safely switched to Bisoprolol (Nerkardou) according to PI decision.\n6. Subject doesn't have other comorbidity according to the assessment of the medical history, electrocardiogram (ECG), echocardiogram vital signs, physical examination, and laboratory results.\n7. Subject with heart rate (HR) ≥ 80 (BPM) at baseline.\n8. Female subjects in childbearing period, and not on a reliable contraceptive method must adhere to the recommended contraceptive methods as detailed in Appendix I.\n9. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial.\n\nExclusion Criteria:\n\n1. Grade III hypertension or malignant hypertension (Hypertensive crisis: Systolic over 180 and\u002For diastolic over 120).\n2. Subjects who are not legible to discontinue current antihypertensives such as calcium channel blockers (CCB), ACE- inhibitors, or diuretics for reasons other than hypertension, or responders to current therapy.\n3. Subjects with heart rates less than (\\\u003C)80 beats at rest.\n4. Subjects with renal impairment (serum creatinine \\> 2.0 milligram per deciliter \\[mg\u002FdL\\])\n5. Subjects with unrecovered pulmonary edema\n6. Subjects with a history of cardiovascular surgeries.\n7. Significant history of hypersensitivity to bisoprolol, amlodipine, other dihydropyridines, or any related products (including excipients of the formulations)\n8. Presence of diabetes mellitus\n9. History or presence of asthma\n10. Presence of significant gastrointestinal, liver, kidney disease, surgery, or any other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs or known to potentiate or predispose to undesired effects.\n11. Use of any enzyme-modifying drugs, including strong inhibitors of CYP enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem, and human immunodeficiency virus \\[HIV\\] antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin, St. John's wort or other herbal medicine known with effect on CYP enzymes) within 28 days before Day 1 of this trial\n12. Acute conditions which might alter renal function (e.g., dehydration, severe infection)\n13. History of suicidal tendency, history of, or disposition to seizures, state of confusion, clinically relevant psychiatric diseases\n14. Positive pregnancy test (only for females of child-bearing potential), or females breastfeeding a child.\n15. Consumption of large quantities of methylxanthine-containing beverages (more than 600 mg caffeine\u002Fday: 1 cup (250 mL) of coffee contains approximately 100 mg of caffeine, 1 cup of black or green tea contains approximately 30 mg and 1 glass of cola contains approximately 20 mg caffeine)\n16. A participant with a life expectancy of fewer than 6 months, or inappropriate for the medication as defined in the Product Information such as acute heart failure or decompensation of heart insufficiency, that requires a therapy with inotropic agents; cardiogenic shock; AV block grade II or III, sick sinus syndrome, sinoatrial heart block; symptomatic bradycardia; symptomatic hypotonia; severe asthma bronchiolus or severe chronic obstructive airways disease; advanced stages of peripheral arterial disease or Raynaud's Syndrome; untreated pheochromocytoma, metabolic acidosis.\n17. Participants who have participated in another research trial involving an investigational product in the past 12 weeks.","21 Years",{"count":49,"type":21},406,[51],"PHASE4","The trial is designed to assess the safety and investigation of the efficacy of a single oral dose of bisoprolol (Nerkardou - Nerhadou) oral dissolvable film (ODF) 5 \\& 10 mg, and patients' compliance in the treatment of essential hypertension. This is a Phase IV, open-label, single-arm, prospective trial where subjects will receive:\n\n1. Bisoprolol (Nerkardou) at an initial dose of 5 (mg) milligrams once daily for 2 weeks.\n2. If the blood pressure would be greater than or equal to 130\u002F80 mmHg after 2 weeks, then the dose will be titrated to 10 mg once daily (non-responders). Dose-Titration will be done at any follow-up visit based on the response.\n3. The total duration of study treatment will be 12 weeks ±2 days, and the total sample size of the study will be 406 participants.",[54],"Essential Hypertension","RECRUITING","2024-08-15",{"date":58,"type":32},"2024-08-19",{"date":60,"type":32},"2024-08-08",{"date":62,"type":21},"2025-04-01",{"name":37,"class":38},1,""]